Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

NCT03287817 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
52
Enrollment
INDUSTRY
Sponsor class

Stopped After reviewing the data and taking into consideration the available treatment landscape in r/r DLBCL, Autolus didn't progress into the Phase II part of the study and submitted a Notification of End of Trial (MHRA reference 46113/0003/001-0016).

Conditions

Interventions

Sponsor

Autolus Limited